You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
研報掘金丨華福證券:維持昆藥集團“買入”評級,看好華潤賦能公司
格隆匯 02-20 15:57

華福證券研報指出,昆藥集團(600422.SH)24Q4單季預計實現歸母扣非1.47億元,23Q4單季度歸母扣非為0.25億元,實現快速增長。2024年系公司公司加入華潤大家庭、與華潤三九穩步推進融合重塑的第二年;聖火完成並表標誌着公司已解決核心產品血塞通軟膠囊“絡泰”與華潤聖火“理洫王”同業競爭問題,全國僅有的兩張血軟批文合為一家,未來公司有望進一步完善三七產業鏈優勢佈局,提升公司在心腦血管疾病治療領域業務規模,持續增厚公司“老齡健康-慢病管理”領域的業績。另外,全國中成藥集採覆蓋面增加,公司血塞通凍幹、軟膠囊、滴丸均中標。看好華潤賦能昆藥集團,以及未來打造銀髮健康產業第一股的戰略核心,維持“買入”評級。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account